Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FLUDARA vs AGRYLIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fludarabine is a purine nucleotide analog that inhibits DNA synthesis by interfering with ribonucleotide reductase and DNA polymerase, leading to cell death in dividing lymphocytes.
Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.
B-cell chronic lymphocytic leukemia (CLL) in adults who have not responded to or have progressed during treatment with at least one standard alkylating-agent regimen,Off-label: non-Hodgkin lymphoma, acute myeloid leukemia, conditioning for hematopoietic stem cell transplantation
Essential thrombocythemia (ET) to reduce elevated platelet counts and the risk of thrombotic complications
25 mg/m^2 intravenously over 30 minutes daily for 5 consecutive days every 28 days.
Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.
Fludarabine phosphate: 0.7-1 h (rapid dephosphorylation). Active metabolite 2-fluoro-ara-A: terminal t1/2 20-30 h (up to 40 h in renal impairment).
Terminal elimination half-life: 1.3–1.5 days (31–36 hours) in patients with ET; allows twice-daily dosing.
Fludarabine is dephosphorylated in serum to 9-β-D-arabinofuranosyl-2-fluoroadenine (F-ara-A), which is then phosphorylated intracellularly to active triphosphate (F-ara-ATP). Further metabolism involves deamination by adenosine deaminase, but the primary route is renal excretion of unchanged drug and metabolites.
Primarily metabolized by CYP1A2 to the active metabolite 3-hydroxyanagrelide, and to a lesser extent by CYP2C19 and CYP2D6.
Renal: 60% excreted unchanged in urine; biliary/fecal: <5% as metabolites.
Renal: 80% (primarily unchanged drug), Biliary/Fecal: 5%
Fludarabine: 19-29% (primarily albumin); 2-fluoro-ara-A: minimal binding.
82–88% bound to plasma proteins (primarily albumin).
Vd: 2.4 L/kg (fludarabine); 0.5-0.9 L/kg (2-fluoro-ara-A, approximating total body water).
30–36 L (approximately 0.45–0.5 L/kg for a 70 kg adult); indicates extensive tissue distribution.
Oral: 55-75% under fasting conditions; food reduces Cmax but not AUC.
Oral: 65–80% (median 73%)
Cr Cl 30-70 m L/min: reduce dose by 20%. Cr Cl <30 m L/min: contraindicated.
No specific GFR-based recommendations; use with caution in renal impairment (Cr Cl <50 m L/min) and monitor closely.
No specific recommendations for hepatic impairment; use with caution in severe hepatic impairment (Child-Pugh C).
Child-Pugh A: No adjustment. Child-Pugh B or C: Reduce initial dose by 50% and titrate cautiously.
Not established for pediatric patients; safety and efficacy not determined.
Children ≥7 years: 0.5 mg orally once or twice daily; adjust based on platelet response. Maximum: 10 mg/day. Not established for <7 years.
No specific adjustment; monitor renal function and hematologic parameters closely.
No specific adjustment; start at lower end of dosing range (0.5 mg twice daily) and monitor renal function and platelet counts closely.
WARNING: FLUDARA MAY CAUSE SEVERE BONE MARROW SUPPRESSION (ANEMIA, THROMBOCYTOPENIA, NEUTROPENIA) AND MAY INDUCE AUTOIMMUNE HEMOLYTIC ANEMIA. PATIENTS SHOULD BE MONITORED CLOSELY FOR HEMATOLOGIC TOXICITY. NEUROTOXICITY (INCLUDING BLINDNESS, COMA, AND DEATH) HAS BEEN REPORTED, PARTICULARLY AT HIGH DOSES (>40 mg/m2/day).
None
Severe bone marrow suppression, particularly thrombocytopenia, anemia, and neutropenia,Autoimmune hemolytic anemia, which can be fatal,Neurotoxicity, especially at high doses; monitor for altered mental status, visual disturbances, seizures,Tumor lysis syndrome, especially in patients with high tumor burden,Immunosuppression and increased risk of opportunistic infections,Pulmonary toxicity including interstitial pneumonitis,Hepatotoxicity and increased liver enzymes,Use with caution in renal impairment; dose adjustment required (Cr Cl <30 m L/min)
Cardiovascular risks: increased risk of ventricular tachycardia, QTc prolongation, and heart failure; use caution in patients with known cardiac disease.,Hematologic effects: monitor complete blood counts regularly due to risk of anemia, leukopenia, or thrombocytopenia.,Hepatic impairment: reduce dose in patients with moderate to severe hepatic impairment.,Renal impairment: use with caution in severe renal impairment.
Hypersensitivity to fludarabine or any component of the formulation,Severe renal impairment (Cr Cl <30 m L/min) unless benefit outweighs risk,Pregnancy (can cause fetal harm),Lactation (discontinue nursing or drug)
Severe hepatic impairment,Known hypersensitivity to anagrelide or any component of the formulation
No specific dietary restrictions. Maintain adequate hydration. Grapefruit juice may interact; avoid excessive consumption. Avoid alcohol due to possible hepatotoxicity.
Grapefruit and grapefruit juice should be avoided as they may increase anagrelide plasma concentrations. No other specific dietary restrictions; however, maintain adequate hydration to reduce risk of crystalluria.
Fludarabine is contraindicated in pregnancy. It is a nucleoside analog with known teratogenic and embryotoxic effects. First trimester exposure is associated with major congenital malformations, particularly neural tube defects, craniofacial anomalies, and limb defects. Second and third trimester exposure can cause fetal growth restriction, myelosuppression, and increased risk of fetal death. Both animal studies and human case reports confirm significant fetal harm.
Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies) at doses less than the human therapeutic dose. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to fetus. First trimester: Avoid due to organogenesis risk. Second and third trimesters: Unknown risks; consider alternative therapy.
No data exist on fludarabine excretion into human breast milk. Given its mechanism of action (DNA synthesis inhibitor) and potential for severe adverse effects (e.g., myelosuppression, carcinogenesis) in a nursing infant, breastfeeding is contraindicated during therapy and for at least 1 week after the last dose. M/P ratio is unknown.
It is not known whether anagrelide is excreted in human milk. No M/P ratio is available. Due to potential for serious adverse reactions in breastfed infants (e.g., thrombocytopenia, cardiovascular effects), advise women not to breastfeed during treatment and for at least 7 days after last dose.
No established dose adjustments exist for fludarabine during pregnancy. Due to increased plasma volume, renal clearance, and altered pharmacokinetics in pregnancy, standard dosing may result in subtherapeutic levels. However, given the high teratogenic risk, use is contraindicated; if unavoidable (e.g., life-threatening maternal condition), consider therapeutic drug monitoring and dose individualization based on AUC, but data are extremely limited and safety cannot be assured.
No specific pharmacokinetic studies in pregnancy. Pregnancy-induced plasma volume expansion may lower drug concentrations, potentially requiring dose adjustment to maintain therapeutic effect. However, due to teratogenicity risks, avoid use in pregnancy. If necessary, start at lowest effective dose (0.5 mg/day) and titrate based on platelet count monitoring, not to exceed 10 mg/day.
Fludarabine is a purine analog used in B-cell chronic lymphocytic leukemia (CLL). It requires dose adjustment in renal impairment (Cr Cl <30 m L/min). Myelosuppression is dose-limiting; monitor blood counts. Use with caution in patients with prior autoimmune hemolytic anemia. Trimethoprim-sulfamethoxazole should be given for Pneumocystis jirovecii prophylaxis. Allopurinol is recommended for tumor lysis syndrome prevention. Administer IV over 30 minutes or longer.
Agrylin (anagrelide) is a phosphodiesterase III inhibitor used to reduce platelet counts in essential thrombocythemia. Monitor platelet count weekly during titration; target <600,000/µL. Avoid in patients with severe hepatic impairment (Child-Pugh C). Use with caution in cardiac disease due to risk of QT prolongation and arrhythmias. Anagrelide may increase bleeding risk, especially when combined with anticoagulants or NSAIDs. Discontinue 4-5 days before elective surgery.
Take this medication exactly as prescribed by your doctor.,You will need regular blood tests to monitor your blood cell counts.,Avoid live vaccines during treatment and for 12 months after.,Report any signs of infection (fever, chills, sore throat) or unusual bleeding/bruising immediately.,Use effective contraception during treatment and for at least 6 months after the last dose.,Drink plenty of fluids to help prevent kidney problems.,Avoid exposure to people with infections.
Take exactly as prescribed; do not skip doses or double up.,Report any signs of bleeding (easy bruising, nosebleeds, black/tarry stools) or palpitations immediately.,Avoid NSAIDs like ibuprofen and aspirin unless directed by your doctor.,Do not consume grapefruit or grapefruit juice while taking this medication.,Inform all healthcare providers (including dentists) that you are on anagrelide.,Store at room temperature away from moisture and heat.
"Roflumilast, a selective phosphodiesterase-4 (PDE4) inhibitor, enhances intracellular cyclic AMP levels, leading to suppression of pro-inflammatory cytokine production and modulation of immune cell function. Fludarabine, a purine analog used in hematologic malignancies, exerts immunosuppressive effects through inhibition of DNA synthesis and lymphocyte apoptosis. Concurrent use may result in additive or synergistic immunosuppression, increasing the risk of severe infections, including opportunistic infections, and potentially delaying immune recovery in patients already immunocompromised due to fludarabine therapy."
"The combination of tacrolimus and fludarabine may increase the risk of toxicity, particularly nephrotoxicity and neurotoxicity, due to additive immunosuppressive effects and potential pharmacokinetic interactions. Fludarabine may inhibit the metabolism of tacrolimus through CYP3A4 competition, leading to elevated tacrolimus levels and increased adverse effects, including renal impairment and neurological symptoms such as tremors and seizures. Close monitoring is required to avoid severe outcomes like opportunistic infections and organ damage."
"Fludarabine may decrease the cardiotoxic activities of Digitoxin."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FLUDARA vs AGRYLIN, answered by our medical review team.
FLUDARA is a Antineoplastic Agent that works by Fludarabine is a purine nucleotide analog that inhibits DNA synthesis by interfering with ribonucleotide reductase and DNA polymerase, leading to cell death in dividing lymphocytes.. AGRYLIN is a Antineoplastic Agent that works by Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FLUDARA and AGRYLIN depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FLUDARA is: 25 mg/m^2 intravenously over 30 minutes daily for 5 consecutive days every 28 days.. The standard adult dose of AGRYLIN is: Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FLUDARA and AGRYLIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FLUDARA is classified as Category C. Fludarabine is contraindicated in pregnancy. It is a nucleoside analog with known teratogenic and embryotoxic effects. First trimester exposure is associated with major congenital . AGRYLIN is classified as Category C. Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.